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Abstract The perioperative administration of selective
cyclooxygenase-2 (COX-2)-inhibitors to avoid postopera-
tive pain is an attractive option: they show favorable gastro-
intestinal tolerability, lack inhibition of blood coagulation,
and carry a low risk of asthmatic attacks. The purpose of
this study was to determine the cerebrospinal fluid (CSF),
plasma, and tissue pharmacokinetics of orally administered
etoricoxib and to compare it with effect data, i.e., COX-2-
inhibition in patients after hip surgery. The study was
performed in a blinded, randomized, parallel group design.
A total of 12 adult patients were included who received
120 mg etoricoxib (n=8) or placebo (n=4) on day 1 post-
surgery. Samples from plasma, CSF, and tissue exudates
were collected over a period of 24 h post-dosing and
analyzed for etoricoxib and prostaglandin E2 (PGE2) using
liquid chromatography-tandem mass spectrometry and
immuno-assay techniques. CSF area under the curve
(AUC) [AUCs(O–24h)] for etoricoxib amounted to about
5% of the total AUC in plasma (range: 2–7%). Individual
CSF lag times with respect to (50%) peak plasma
concentration were ≤2 h in all but one case (median: 1 h).
PGE2 production in tissue was significantly blocked by the
COX-2 inhibitor starting with the appearance of etoricoxib
in tissue and lasting for the whole observation period of
24 h (P<0.01). In conclusion, etoricoxib reaches the CSF
and site of surgery at effective concentrations and reduces
PGE2 production at the presumed site of action.
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Introduction
Surgical trauma induces cyclooxygenase-2 (COX-2) upregu-
lation and subsequent synthesis of prostaglandins locally
(Lipsky et al. 1998) and in the central nervous system
(CNS; Dolan et al. 2003). This leads to peripheral and central
hyperalgesia (Woolf and Chong 1993; Reinold et al. 2005).
Selective COX-2 inhibitors appear to block both peripheral
and central hyperalgesia, but havelittleor no effectonplatelet
aggregation and asthma. These characteristics make them
attractive candidates for perioperative use (Viola et al. 2007;
Schwartz et al. 2008). Etoricoxib (a new selective COX-2
inhibitor available in many countries) has been reported to
reduce postoperative pain after orthopedic surgery (Toivonen
et al. 2007; Turan et al. 2008). When administered postop-
eratively to patients who had undergone hip replacement,
etoricoxib provided analgesia similar to controlled release
naproxen and superior to placebo (Rasmussen et al. 2005).
Prostaglandin E2 (PGE2) is the predominant eicosanoid
released in damaged tissue (Samad et al. 2002). Animal
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DOI 10.1007/s00210-009-0482-0data demonstrate an increase in spinal PGE2 after peripheral
injury (Dirig and Yaksh 1999). Spinal administration of a
COX-2 inhibitor in an animal inflammatory model de-
creased peripheral inflammation-induced central PGE2
concentrations and mechanical hyperalgesia (Woolf and
Chong 1993; Samad et al. 2001; Reinold et al. 2005). In
rats, similar results were demonstrated in a post-surgical
pain model (Kroin et al. 2002, 2004). It seems attractive to
propose that COX-2 inhibitors act equally in humans due to
a similar cerebrospinal fluid (CSF) and tissue drug uptake
compared to animals. However, interspecies differences in
blood brain barrier and different degrees of protein binding
may alter the drug uptake at these sites of action (Shen et al.
2004; Summerfield et al. 2006). Therefore, clinical inves-
tigations in humans are needed before defining the proper
dosing of etoricoxib in the perioperative setting. There are
only a few recent studies characterizing plasma and CSF
pharmacokinetics of COX-2 inhibitors (celecoxib, rofe-
coxib, and valdecoxib) in humans (Buvanendran et al.
2005; Dembo et al. 2005). A recentpharmacodynamicstudy
with rofecoxib in humans to evaluate CSF interleukin 6
and PGE2 concentrations following orthopedic surgery
demonstrated increased levels of these mediators after
surgery (Buvanendran et al. 2006). CSF PGE2 concentra-
tions were positively correlated with postoperative pain and
the content of PGE2 in tissue exudates correlated with the
functional outcome (Buvanendran et al. 2006). Since
rofecoxib and valdecoxib have been removed from the
market, human data for the remaining COX-2 inhibitors,
such as etoricoxib, are missing.
We set out to study the pharmacokinetics of etoricoxib in
plasma, CSF, and tissue exudate in order to optimize the
dosing and therapeutic benefits of this drug. In this pilot
study, we characterized in patients the time course of
etoricoxib appearance in CSF and damaged tissue (tissue
exudates from surgical site) and determined its effect on
PGE2 production at these sites of analgesic action.
Methods
After approval from the German authorities and the
Institutional Ethics Review Board, 12 male and female
patients (age 55–80 years) with osteoarthritis undergoing
elective primary single hip arthroplasty were consented. All
patients were recruited at the Department of Orthopedics,
HELIOS Klinikum Berlin–Buch, Germany. The clinical
trial is registered at EudraCT (#2005-003854-80) and at
ClinicalTrails.gov (#NCT00746720). The study was con-
ducted according to the Declaration of Helsinki on
biomedical research involving human subjects (Somerset
West amendment). All patients gave their informed consent
prior to their inclusion in the study. One patient dropped out
due to detectable etoricoxib plasma concentrations before
receiving the first dose; another patient was unblinded
2 days after drug administration due to an adverse event
(hemolytic anemia and hemoglobin decrease) which was
unlikely related to the study drug. This patient received
diclofenac at day 3 post-surgery as a routine medication and
was found positive for diclofenac antibodies.
Patients and study design
Exclusion criteria were: renal insufficiency (serum creati-
nine >1.5 mg/dL), recent major trauma or systemic
infection (within 3 months), history of usage of corticoste-
roid medication, or chronic opioids (within 3 months),
conditions likely to affect prostaglandin levels and
conditions contraindicating spinal anesthesia. In addition,
patients were excluded if they had the following
characteristics: hypersensitivity to any component of the
study medication; uncontrolled hypertension defined as
s y s t o l i cb l o o dp r e s s u r e> 1 6 0m mH ga n dd i a s t o l i c
pressure >90 mm Hg during rest at two repeated measure-
ments; congestive heart failure (NYHA II–IV); cerebrovascu-
lar disease; established ischemic heart disease (including
patients who had recently undergone coronary artery bypass
graft surgery or angioplasty); elevated liver function enzymes
(threefold above normal range); patients who had developed
signs of asthma, acute rhinitis, nasal polyps, angioneurotic
edema, or urticaria following the administration of acetylsa-
licylic acid or other non-steroidal anti-inflammatory drugs;
pregnancy and lactation; patients with active peptic ulcer-
ations or active gastro-intestinal bleeding; and inflammatory
bowel disease.
Preoperative demographic data were collected and all
preoperative medications including dose, route, and duration
were recorded. Pain scores were assessed using a numerical
rating scale (11 point category scale: 0 = no pain, 10 = worst
possible pain; Downie et al. 1978). Thus, the global (overall)
pain and the specific pain for the operative hip at rest and
passive movement were obtained before and after surgery.
The study was restricted to a sampling period of 24 h
due to safety reasons (overall sampling volume for CSF and
plasma). Patients received the spinal anesthetic bupivacaine
0.5% (7.5–10 mg) via an intrathecal (IT) catheter placed at
the lumbar 3–4o r4 –5 interspace. They were maintained at
normothermia in the operating room by supporting means,
including warmed intravenous fluids. Postoperatively, 0.01%
bupivacaine was infused intrathecally at a continuous rate
superimposed by patient controlled IT boluses. Initial basal
infusion rate was 4 mL/h with patient controlled boluses of
up to 1 mL q 10 min and a 4-h lockout of 40 mL. The
patients were allowed to titrate intrathecal requirements for
analgesia using a previously applied analgesic efficacy
protocol (Buvanendran et al. 2003). Intravenous morphine
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breakthrough pain. Total drug consumption was recorded. If
patients had a temperature >39°C, oral acetaminophen 1.0 g
was administered after contact with one of the investigators.
A standardized surgical technique of non-cemented hip
arthroplasty was used for all patients.
As the study was focused on the PK data from three
matrixes during absorption period, only four patients served
as placebo controls. On postoperative day 1, eight patients
received oral etoricoxib 120 mg at 7.00 AM and four
patients received a placebo. The study was blinded to
patients and the investigators, but not to the analytical
department. Blood (3 mL) and CSF samples (0.5 mL) were
collected before and at the following time points after drug
administration: 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, and 24 h (eight
time points). The initial 1 ml of each CSF sample was
discarded to account for dead space in the catheter and to
avoid possible dilution artifacts regarding the intrathecally
applied bupivacaine. The postoperative analgesic IT solu-
tion was administered to provide continuous analgesia for
the patients between sampling time points.
Tissue exudates (hip drain) were collected at 0.0
(before), 1.0, 3.0, 8.0, 12.0, and 24 h after drug adminis-
tration. One hour before the scheduled collection time, the
Redon drain system (B. Braun AG, Melsungen, Germany)
was emptied and the exudate was collected over the next
60 min (additional sampling times at 2.0, 7.0, 11.0, and
23 h post-medication). Drain fluids were centrifuged and
the supernatant frozen at −30°C and sent for analysis.
Pharmacokinetic analysis
Following oral etoricoxib, pharmacokinetic parameters
were determined in plasma, tissue exudate, and CSF in
each subject using a liquid chromatography-tandem mass
spectrometry (LC-MS/MS). The analytical method was
adapted from published work on plasma using phenazone
as an internal standard (Brautigam et al. 2003). The
detection was performed on API 4000 (Applied Biosys-
tems, Langen, Germany) and determination of the limits of
quantification (LOQ) for etoricoxib plasma, CSF, and tissue
exudates were carried out according to the Food and Drug
Administration (FDA) guidelines (US Department of
Health and Human Services, 2001). The LOQ for etori-
coxib was 0.2 ng/mL in all three matrixes. The analytical
method was validated over the concentration range 0.2–
200 ng/mL. The area under the curve (AUC) [ng·h/mL]
from 0 to 24 h was calculated for both CSF and plasma data
using the linear trapezoidal method. The fraction of plasma
etoricoxib in the CSF was calculated from the ratio of
AUCCSF to AUCplasma at each sampling time.
PGE2 analysis from tissue samples was performed using
enzyme linked immunoassay kits (Cayman Chemical, MI,
USA). The LOQ for PGE2 was 15 pg/mL. CSF samples
were analyzed for PGE2 using LC-MS/MS methods, which
were developed in this study using a stable isotope of
prostaglandin D2–d4. The solid phase extraction method
and the LC-MS/MS conditions were adjusted to our API
4000 system using previous publications (Nithipatikom et al.
2003; Schmidt et al. 2005). The lower LOQ was 25 pg/mL
and the upper LOQ was 200 pg/mL according to FDA
guidelines (US Department of Health and Human Services
2001). The PGE2 concentrations at the central (CSF) and
peripheral (tissue exudate) sites over time were compared
between the study groups.
Secondary parameters
Pain scores at rest and passive movement of the operated
hip were assessed at 4.0, 8.0, 12, 24, 26, 32, and 48 h time
points after study drug administration. The total IT
medication consumption, the number of patient activated
requests, delivered boluses, and time of requests were
documented. Tympanic temperature was monitored at the
preoperative visit and at each blood and CSF measurement
time points.
Hematology comprising a complete blood count with
counts of leukocytes and platelets was obtained preopera-
tively and postoperatively as per routine standard care.
Blood products transfused in the perioperative phase were
recorded. In addition, coagulation parameters were mea-
sured and recorded (preoperatively and postoperatively).
Patients rated their sleep disturbance due to pain at 24 h
after surgery (0 = no sleep disturbance to 10 = greatest
sleep disturbance; Buvanendran et al. 2003).
Statistical analysis and sample size estimation
Demographic and other univariate data were analyzed using
t tests, χ
2 tests, and Fisher’s exact tests, the Mantel–
Haenszel test, or the Mann–Whitney U-test, contingent on
the scale and distributional characteristics of the variables,
and applying the Bonferroni step-down correction method
to adjust for multiple comparisons. Unless otherwise
indicated, descriptive statistics are reported as mean and
standard deviation (SD) for continuous normally distributed
variables, or as median and interquartile range for ordinal or
non-normally distributed variables, while dichotomous
variables are reported using counts and/or percentages.
Outcomes with measures at multiple time points were
analyzed using repeated-measures analysis of variance with
an auto-regressive covariance structure to account for the
correlated nature of individual patient contributions.
Initial pilot data obtained with rofecoxib indicated a
significant reduction in CSF PGE2 concentrations, but with
variability differing between the two groups (Buvanendran
Naunyn-Schmied Arch Pharmacol (2010) 381:127–136 129et al. 2006). In an effort to address this issue in our actual
study, the treatment group was oversampled at a rate of 2 to
1 as compared to the placebo group. Assuming a threefold
reduction in CSF PGE2 concentrations with a SD of 60 pg/
mL for the treatment group and 40 pg/mL for the placebo, a
total sample size of 12, with eight treatment subjects and
four placebo subjects, will provide 84% power to detect a
significant difference for a two-sided t test [data for sample
size estimation were taken from (Buvanendran et al. 2006)].
Relationships between variables were evaluated using the
Pearson product-moment correlation. P<0.05 was used to
determine statistical significance. All statistical analyses
were performed using SAS version 9.1 (SAS Institute Inc,
Cary, NC, USA).
Results
An analysis of the demographic variables for the two
groups of patients shown in Table 1 demonstrates that there
were no significant differences. The duration of surgery and
blood loss for the two groups was also not different. For the
active treatment group, hematological parameters such as
hemoglobin were slightly lower in the postoperative period
compared to preoperative values. There were no meaning-
ful differences in postoperative pain and opioid consump-
tion, neither in the pain scores at rest globally and also
during movement between the two groups of patients.
During the 48 h postoperative period, the amount of
intrathecal drug (IT boluses of bupivacaine) administered,
titrated to provide postoperative analgesia, did not differ
between the two groups. Similarly, there was no difference
in the use of additional analgesics, but the study was not
designed to detect such differences as both groups received
standard IT and parenteral pain medication at this state
post-surgery.
Prostaglandin E2 concentrations
We observed a significant difference in the PGE2 concen-
tration in the tissue exudate between the etoricoxib and
placebo group despite the small number of patients in the
placebo group (Fig. 1 and Table 2). This difference became
significant in the samples retrieved 5 h after medication. It
lasted 18 h till the end of the observation period. There was
a time lag between exudate production and sample recovery
from the Redon drain. The material sampled at, e.g., 5 h
was produced about 2 h after medication. Altogether, we
found a negative correlation (R=−0.7; P=0.02) between the
concentration of etoricoxib and that of PGE2 in the tissue
exudates.
The CSF PGE2 concentrations were below the quantifi-
cation limit of the LC-MS/MS method in most cases.
Therefore, AUCs could not be calculated and group
analysis was not performed for this parameter.
Etoricoxib concentrations
A summary of the pharmacokinetic data is given in Table 3.
The 24-h concentration-time curves of etoricoxib in plasma,
CSF, and tissue exudate are shown in Fig. 2 with
semilogarithmic presentation. Data with linear scaling are
given in Figs. 1 and 3a, respectively. The drug concentra-
tion in the CSF lagged behind that of plasma. In plasma,
etoricoxib concentrations peaked at 1 h on average (see
Fig. 2). At that time, CSF concentrations were measurable,
but reached only about a third (34%) of the peak
concentration which was observed at 8 h (Fig. 3a and
Table 3). In both compartments, a plateau was reached after
about 2 h (compare Fig. 2). The CSF/plasma concentration
ratio of the drug in absolute terms was 0.016 at 1 h and
increased to 0.030 and 0.057 at 2 and 4 h, respectively. On
time average, the maximum CSF/plasma ratio (0.063)
occurred at 8 h. Individual maximum concentration ratios
were observed to be 7.3% (±2.1) between 3 and 12 h post-
drug administration. The mean CSF/plasma ratio with
respect to AUC0–24h was 4.4% (see Table 3 and Fig. 3b).
The median CSF lag time with respect to 50% of the
peak concentration in plasma was 0.5 (1 if patient R09 is
included) h, range 0-2 (7 if R09 included) h. One patient
(R09) showed an extended lag time (7 h) which may be
due to a second fractionate absorption resulting in a higher
CSF peak concentration (108 ng/mL) at 8 h post-
medication (see Table 4).
Table 1 Demographic characteristics of the patients
Placebo (n=3)
a Etoricoxib (n=8) P value
Mean (SD) Mean (SD)
Age (yr) 67.4 (2.4) 72.1 (5.4) 0.1963
Weight (kg) 88.5 (16.3) 77.4 (8.9) 0.2031
Height (cm) 171 (9) 163 (8) 0.2442
Sex (counts) 0.3869
b
Female/male 1/2 5/3
Race (counts) ND
Caucasian 3 (100%) 8 (100%)
Duration of surgery (min) 56 (19) 39 (6) 0.2609
Intra-OP BL (mL) 300 (0)
c 440 (114)
c 0.0516
Values are mean (standard deviation) unless otherwise indicated
SD standard deviation, Intra-OP BL blood loss during surgery, ND not
done (statistic cannot be computed)
aOne patient in the placebo group dropped out due to clinical reasons
bChi-square test, due to low counts P value may be biased
cDue to missing values n=2/n=5 in the placebo/etoricoxib group
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lag behind plasma and CSF with virtually no drug detected at
2.5 h (Figs. 1 and 2). The virtual lag time (without correction
for the delay of sampling) for 50% peak concentration
ranged between 1.5 and 6.5 h (median 4 h; see Table 4).
Discussion
This is the first study in humans to characterize the
pharmacokinetics of the COX-2 inhibitor etoricoxib in the
CSF, plasma, and tissue exudate simultaneously and in
conjunction with effect data from the putative sites of
action. The main finding of this pilot study is that plasma
etoricoxib enters the CSF with a lag time of about 1 h and
reaches a CSF/plasma concentration ratio of approximately
5%. At the site of surgery, we observed that PGE2
production was still high 1 day after surgery. In the placebo
group, it increased further whereas it decreased significant-
ly in the treatment group beginning with the appearance of
etoricoxib in the wound fluid.
It was not the aim of this study to investigate the
analgesic effect of etoricoxib in patients. This is obvious
from the fact that the patients received complete routine
Placebo (n=3)
b Etoricoxib (n=8) P value
Mean (SD) Mean (SD)
Overall difference for all values
PGE2 Hip (n=88) 33.7 (22.7) 11.9 (10.2) <.0001
Regression model
PGE2 Hip
Interaction <.0001
a
Main effect 0.0073
a
Time points contrasts
c
Pre 15.4 (14.6) 7.7 (5.4) 0.3158
−0.5 h 21.2 (5.0) 15.1 (9.1) 0.4406
0.5 h 20.1 (3.5) 18.1 (8.8) 0.4103
1.5 h 27.8 (5.5) 24.4 (10.5) 0.2002
2.5 h 27.4 (10.9) 20.9 (16.1) 0.4170
5.0 h 53.9 (24.5) 16.9 (13.6) <.0001
a
7.5 h 57.0 (39.8) 12.1 (9.3) <.0001
a
9.5 h 50.4 (27.7) 7.9 (6.0) <.0001
a
11.5 h 41.1 (24.1) 6.4 (5.1) 0.0001
a
17.5 h 27.9 (20.1) 6.2 (6.2) 0.0061
a
23.5 h 24.2 (23.0) 2.3 (0.7) 0.0141
a
Table 2 Statistical summary
for PGE2 concentrations
[ng/mL] in tissue exudate
All <LOQ values set to max of
25 pg/mL
aStatistically significant at
alpha = 0.05
b One patient in the placebo
group dropped out due to
clinical reasons
cTime points are midpoints of
collection intervals
PGE2 = prostaglandin E2;S D=
standard deviation
PGE2 values were modeled
using repeated measures analy-
sis of variance. Maximum like-
lihood parameter estimates were
generated using an auto-
regressive mixture model.
Fig. 1 Time course of
etoricoxib and prostaglandin E2
(PGE2) concentrations in tissue
exudates. PGE2 concentrations
are shown as differences to
baseline values. Sample times
are midpoints of collection
intervals (means ± SEM; place-
bo group n=3; etoricoxib group
n=8). Absolute PGE2 concen-
trations and statistical data are
given in Table 1
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24 h after surgery, i.e., at a time when postoperative pain
has subsided considerably and body functions have
recovered. We observed no perioperative side effects
related to the administration of etoricoxib. Signs of higher
blood loss in the etoricoxib compared to the placebo group
(see Table 1) were not caused by the drug, since they
occurred before drug administration.
Our pharmacokinetic results are comparable to those
seen in healthy volunteers, but indicate differences as well.
Fast absorption and slow elimination is seen in our elderly
postoperative patients, too, but the time to peak is more
variable. Consistent with data published previously, a twin-
peak pattern was observed in the plasma concentration–
time curve of etoricoxib after administered orally to healthy
subjects (Dallob et al. 2003; Agrawal et al. 2003a). Possible
mechanisms for secondary peaks include biphasic dissolu-
tion or fractionated gastric emptying, and presence of two
different absorption sites or enterohepatic recycling. All
may be pertinent to our results.
In addition, we could show that a fast transfer of
effective concentrations of etoricoxib into the CNS fluid
and into the tissue exudates occurs. Indeed, meaningful
(COX-2 inhibitory) CSF concentrations were reached
Table 3 Pharmacokinetic parameters of etoricoxib comparing cerebrospinal fluid (CSF) and plasma data
Plasma CSF
n=8 (all patients) n=5
a n=5
a
AUC0–24h [h × ng/mL]
b 22,197 (5,780) 22,587 (5,759) 955 (354)
tmax [h]
c 3( 1 –24) 4 (1–24) 8 (2–12)
cmax [ng/mL]
b 1735.1 (1206.4) 1437.6 (533.8) 68.4 (30.6)
CSF/plasma ratio AUC0–24h [%]
d 4.4 (2–7)
tmax [h] for CSF/plasma conc. ratio
c 8( 3 –12)
CSF/plasma conc. ratio [%] at tmax
b 6.3 (2.0)
Max. CSF/plasma conc. ratio [%]
e 7.3 (2.1)
SD standard deviation, conc. concentration
aSubgroup analysis without data from three patients due to incomplete CSF samples
bMean (± SD)
cMedian (range)
dIndividual CSF/plasma ratios were calculated using AUC0–24h; mean (range) data are given in percentage values
eMax. CSF/plasma ratios were calculated using individual maximal concentration ratios (mean ± SD) data are given in percentage values
Fig. 2 Etoricoxib concentrations
in three different matrixes
(plasma, cerebrospinal fluid
[CSF] and tissue exudates, semi
logarithmical presentation). Not
quantifiable concentrations were
set to the LOQ of 0.2 ng/mL
(means ± SEM; n=8). Tissue
exudate sampling times are mid-
points of collection intervals.
N o t e :i tt o o ka b o u t2hu n t i l
tissue exudate reached the end of
the Redon drain
(sample recovery)
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concentration in CSF fluid amounted to about a 1/20 of that
seen at corresponding times in plasma (AUC0–24h and max.
concentration ratios; Table 3 and Fig. 3b). The maximum
etoricoxib CSF/plasma ratio (6%) occurred at 8 h. Similar
ratios were seen with valdecoxib (4%) and celecoxib (1%)
at 6 h after drug administration. The ratio is reported
somewhat higher for rofecoxib (15–20%) with a
Table 4 Individual lag times [h] of etoricoxib for tissue exudate and cerebrospinal fluid (CSF)
Patient # R01 R02 R05 R06 R07 R09 R10 R12 MEDIAN MEAN
Plasma vs. Tissue exudate 4 4 ND 1.5 6.5 ND 3 ND 4 3.8
Plasma vs. CSF 1 2 (2) 0 (3) 7 (0) 0 1 2
ND sample not done, () invalid data due to missing values
Lag times were calculated with respect to 50% of peak concentrations
Fig. 3 a Plasma and
cerebrospinal fluid (CSF) con-
centrations after administration
of 120 mg etoricoxib orally to
eight patients (linear presenta-
tion, means ± SEM). b
Corresponding time course of
individual and mean CSF/plas-
ma concentration ratios indicat-
ing the relative etoricoxib
penetration into the CSF; mean
data (black) are based on com-
plete data sets from five patients
only, but all individual patient
data (n=8) are presented
(patients data, gray); descriptive
data are given in Table 3
Naunyn-Schmied Arch Pharmacol (2010) 381:127–136 133corresponding lag time (Buvanendran et al. 2005; Dembo et
al. 2005). The (time averaged) maximum CSF concentra-
tion was nearly 70 ng/mL for etoricoxib (Table 3), which
exceeds the concentrations found in CSF for rofecoxib (40–
60 ng/mL), valdecoxib (25 ng/mL), and celecoxib (2 ng/mL)
after an oral dose for acute pain (Buvanendran et al. 2005;
Dembo et al. 2005). This reflects the higher dose of
etoricoxib (120 mg), as compared to rofecoxib (50 mg) and
valdecoxib (40 mg) and the low bioavailability of celecoxib
(20–60% at 200 mg; Brune and Hinz 2004;H i n ze ta l .
2007). CSF fluid is almost free of plasma proteins, and
etoricoxib (as well as other COX-2 inhibitors), being
highly bound (92%) to plasma proteins (Agrawal et al.
2003b), should reach concentrations in CSF similar to the
free fraction in plasma. It is commonly accepted that
uptake into the CNS is restricted to the unbound plasma
fraction (Wilkinson 1983). We estimated the CSF/plasma
ratio of the unbound fractions (CSF/Pu) at equilibrium (2–
24 h). It was about 0.56 (SD±0.24). A similar brain/blood
ratio for etoricoxib was reported in animals (0.66; SD±0.04)
(Summerfield et al. 2006). Both estimates hint at a
comparable CNS transfer rate of etoricoxib in man and rats.
CSF/Pu ratios for rofecoxib, valdecoxib, and celecoxib
werereportedbefore.Theestimatesrangebetween1.5and1.7
(Demboetal.2005). These data,clearlyabove 1.0,suggest an
accumulation of these more lipophilic drugs in the CSF (Shen
et al. 2004). The data quoted here were derived, however, in
an unusual study. The volunteers received therapeutic doses
of all three drugs at the same time. Therefore, complex
interactions appear possible (Dembo et al. 2005).
The CSF concentrations of etoricoxib observed can be
related to those which are required for 50% of COX-2
inhibition (IC50). Different IC50 values for several COX-2
inhibitors are reported. Most derive from in vitro assays
including the original whole blood assay introduced by
Patrignani (Patrignani et al. 1994). In this version of the
assay, drug is added to human blood in vitro and the IC50
values defined. The published in vitro IC50 data for
etoricoxib are lower than ex vivo results. In vitro data vary
considerably from 0.26 to 0.5 µM for etoricoxib, from 0.19
to 0.93 µM for celecoxib, or from 0.1 to 0.65 µM for
valdecoxib (Tacconelli et al. 2002; Gierse et al. 2005; Esser
et al. 2005; Ushiyama et al. 2008). Data from ex vivo whole
blood assays are limited or missing in order to compare
between different COX-2 inhibitors. In this version of the
assay, the drugs are given to volunteers and the COX-2
inhibition will be measured in blood containing the drug
(Patrignani et al. 1994; Panara et al. 1998). In a recent study,
using the ex vivo whole blood assay, Dallob determined the
IC50 to be 1 µM (about 360 ng/mL) after a single dose of
120 mg etoricoxib (Dallob et al. 2003).
In our patients, meaningful (probably effective) concen-
trations of etoricoxib (>360 ng/mL) appeared during the
first hour in plasma applying the conservative ex vivo IC50
data from Dallob et al. (Dallob et al. 2003). We observed
comparable concentrations [free fraction 8% (Agrawal et al.
2003b)] of etoricoxib in the CSF (>29 ng/mL; >0,08 μM)
1 h later. This CNS lag time compares favorably with the
onset of antipyretic action of etoricoxib at about 2 h post-
dose in monkeys (Riendeau et al. 2001). Former studies in
patients have shown that etoricoxib interferes with surgical
pain within the first 2 h after administration (Clarke et al.
2009). In contrast to this observation are those published by
Smirnov et al. (Smirnov et al. 2008). These authors
investigated the effect of etoricoxib after thyroid surgery
and found that it was not analgesic before 6 h after surgery.
The difference may be explained by the fact that patients
with thyroid dysfunction do not suffer from pain before
surgery. Consequently, only surgery will induce COX-2 in
the central nervous system de novo which, according to our
knowledge, should take a few hours. That would explain
the delayed onset despite probably fast absorption of
etoricoxib in these patients.
A former investigation employing rofecoxib demonstrated
that PGE2 concentrations in the CSF started to decline
shortly after drug administration (Buvanendran et al. 2006).
In contrast to this previous study, we sampled CNS fluid not
directly following surgery, but 24 h thereafter. We found
only low PGE2 concentrations (at the quantification limit) in
CSF of treated and not-treated patients. These low concen-
trations appeared to decrease further in several patients on
etoricoxib at or below the detection limit of our assay.
Therefore, these data were not shown.
However, we observed increasing PGE2 concentrations at
the site of surgery in the placebo group. Obviously, COX-2
was already induced following surgery at the day before.
Consequently, we could observe an immediate action of
etoricoxib when entering the inflamed tissue. Similar effects
have been reported for rofecoxib, but without simultaneous
sampling of PGE2 and drug concentration data at the wound
site (Buvanendran et al. 2005, 2006). It should be kept in
mind that the appearance and persistence of etoricoxib
concentrations sufficient to interfere with PGE2 production
may be instrumental for achieving inhibition of heterotopic
ossification which has been shown for several drugs,
including COX-2 selective inhibitors, but not yet for
etoricoxib (Sodemann et al. 1990; Barthel et al. 2002;
Buvanendran et al. 2007).
In conclusion, our pilot study supports the contention
that the selective COX-2 inhibitor etoricoxib may be
suitable for perioperative treatment in patients who are not
at high risk for cardiovascular conditions. Indeed, we found
that etoricoxib reaches meaningful CSF and wound fluid
concentrations shortly after administration. Following the
appearance of effective concentrations in these compart-
ments, inhibition of prostaglandin production was observed.
134 Naunyn-Schmied Arch Pharmacol (2010) 381:127–136It appears plausible that this goes along with antihyper-
algesia. Based on the results presented, it is planned to
investigate the perioperative application of etoricoxib in a
further study aimed at defining the analgesic effectiveness of
etoricoxib under these conditions. The drug will be given
before surgery and the postoperative pharmacokinetics and
analgesic effects monitored thereafter.
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